Cargando…

Prescription drug monitoring program utilization in Kentucky community pharmacies

OBJECTIVE: Identify characteristics of Kentucky community pharmacists and community pharmacists’ practice environment associated with utilization of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). METHODS: Surveys were mailed to all 1,018 Kentucky pharmacists with a KAS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wixson, Sarah E., Blumenschein, Karen, Goodin, Amie J., Talbert, Jeffery, Freeman, Patricia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482842/
https://www.ncbi.nlm.nih.gov/pubmed/26131042
_version_ 1782378507122245632
author Wixson, Sarah E.
Blumenschein, Karen
Goodin, Amie J.
Talbert, Jeffery
Freeman, Patricia R.
author_facet Wixson, Sarah E.
Blumenschein, Karen
Goodin, Amie J.
Talbert, Jeffery
Freeman, Patricia R.
author_sort Wixson, Sarah E.
collection PubMed
description OBJECTIVE: Identify characteristics of Kentucky community pharmacists and community pharmacists’ practice environment associated with utilization of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). METHODS: Surveys were mailed to all 1,018 Kentucky pharmacists with a KASPER account and an additional 1,000 licensed pharmacists without an account. Bivariate analyses examined the association between KASPER utilization and practice type (independent or chain) and practice location (rural or urban). A multivariate Poisson regression model with robust error variance estimated risk ratios (RR) of KASPER utilization by characteristics of pharmacists’ practice environment. RESULTS: Responses were received from 563 pharmacists (response rate 27.9%). Of these, 402 responses from community pharmacists were included in the analyses. A majority of responding pharmacists (84%) indicated they or someone in their pharmacy had requested a patient’s controlled substance history since KASPER’s inception. Bivariate results showed that pharmacists who practiced in independent pharmacies reported greater KASPER utilization (94%) than pharmacists in chain pharmacies (75%; p<0.001). Multivariate regression results found utilization of KASPER varied significantly among practice environments of community pharmacists with those who practiced in an urban location (RR: 1.11; [1.01–1.21]) or at an independent pharmacy (RR: 1.27; [1.14–1.40]) having an increased likelihood of KASPER utilization. CONCLUSION: Utilization of KASPER differs by community pharmacists’ practice environment, predominantly by practice type and location. Understanding characteristics of community pharmacists and community pharmacists’ practice environment associated with PDMP use is necessary to remove barriers to access and increase utilization thereby increasing PDMP effectiveness.
format Online
Article
Text
id pubmed-4482842
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-44828422015-06-30 Prescription drug monitoring program utilization in Kentucky community pharmacies Wixson, Sarah E. Blumenschein, Karen Goodin, Amie J. Talbert, Jeffery Freeman, Patricia R. Pharm Pract (Granada) Original Research OBJECTIVE: Identify characteristics of Kentucky community pharmacists and community pharmacists’ practice environment associated with utilization of the Kentucky All Schedule Prescription Electronic Reporting Program (KASPER). METHODS: Surveys were mailed to all 1,018 Kentucky pharmacists with a KASPER account and an additional 1,000 licensed pharmacists without an account. Bivariate analyses examined the association between KASPER utilization and practice type (independent or chain) and practice location (rural or urban). A multivariate Poisson regression model with robust error variance estimated risk ratios (RR) of KASPER utilization by characteristics of pharmacists’ practice environment. RESULTS: Responses were received from 563 pharmacists (response rate 27.9%). Of these, 402 responses from community pharmacists were included in the analyses. A majority of responding pharmacists (84%) indicated they or someone in their pharmacy had requested a patient’s controlled substance history since KASPER’s inception. Bivariate results showed that pharmacists who practiced in independent pharmacies reported greater KASPER utilization (94%) than pharmacists in chain pharmacies (75%; p<0.001). Multivariate regression results found utilization of KASPER varied significantly among practice environments of community pharmacists with those who practiced in an urban location (RR: 1.11; [1.01–1.21]) or at an independent pharmacy (RR: 1.27; [1.14–1.40]) having an increased likelihood of KASPER utilization. CONCLUSION: Utilization of KASPER differs by community pharmacists’ practice environment, predominantly by practice type and location. Understanding characteristics of community pharmacists and community pharmacists’ practice environment associated with PDMP use is necessary to remove barriers to access and increase utilization thereby increasing PDMP effectiveness. Centro de Investigaciones y Publicaciones Farmaceuticas 2015 2015-06-15 /pmc/articles/PMC4482842/ /pubmed/26131042 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Wixson, Sarah E.
Blumenschein, Karen
Goodin, Amie J.
Talbert, Jeffery
Freeman, Patricia R.
Prescription drug monitoring program utilization in Kentucky community pharmacies
title Prescription drug monitoring program utilization in Kentucky community pharmacies
title_full Prescription drug monitoring program utilization in Kentucky community pharmacies
title_fullStr Prescription drug monitoring program utilization in Kentucky community pharmacies
title_full_unstemmed Prescription drug monitoring program utilization in Kentucky community pharmacies
title_short Prescription drug monitoring program utilization in Kentucky community pharmacies
title_sort prescription drug monitoring program utilization in kentucky community pharmacies
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482842/
https://www.ncbi.nlm.nih.gov/pubmed/26131042
work_keys_str_mv AT wixsonsarahe prescriptiondrugmonitoringprogramutilizationinkentuckycommunitypharmacies
AT blumenscheinkaren prescriptiondrugmonitoringprogramutilizationinkentuckycommunitypharmacies
AT goodinamiej prescriptiondrugmonitoringprogramutilizationinkentuckycommunitypharmacies
AT talbertjeffery prescriptiondrugmonitoringprogramutilizationinkentuckycommunitypharmacies
AT freemanpatriciar prescriptiondrugmonitoringprogramutilizationinkentuckycommunitypharmacies